Novavax (NASDAQ:NVAX) Issues Earnings Results, Beats Estimates By $2.22 EPS

Novavax (NASDAQ:NVAX - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping analysts' consensus estimates of $0.71 by $2.22, Zacks reports. The firm had revenue of $666.66 million for the quarter, compared to analyst estimates of $204.08 million. During the same period last year, the company posted ($1.05) earnings per share. The firm's quarterly revenue was up 610.3% compared to the same quarter last year. Novavax updated its FY 2025 guidance to EPS.

Novavax Stock Up 6.2%

Shares of Novavax stock opened at $6.34 on Tuesday. The company has a market cap of $1.02 billion, a PE ratio of -2.81, a price-to-earnings-growth ratio of 2.85 and a beta of 3.21. Novavax has a 52 week low of $5.01 and a 52 week high of $23.86. The business has a 50 day moving average price of $6.83 and a 200-day moving average price of $7.98.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVAX. JPMorgan Chase & Co. dropped their price target on Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research note on Friday. BTIG Research started coverage on Novavax in a research note on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective for the company. Finally, TD Cowen raised Novavax to a "hold" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $17.71.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.